Comparisons of oncologic outcomes between triple-negative breast cancer (TNBC) and non-TNBC among patients treated with breast-conserving therapy

Yonsei Medical Journal

Volumn 57, Issue 5, 2016, Pages 1192-1198

  Kim, Sanghwa ^a   Park, Hyung Seok ^a   Kim, Jee Ye ^a   Ryu, Jegyu ^a   Park, Seho ^a   Kim, Seung Il ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Mastectomy; Segmental; Triple negative breast neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CONSERVING THERAPY; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; NON TRIPLE NEGATIVE BREAST CANCER; ONCOLOGIC OUTCOME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; MORTALITY; PARTIAL MASTECTOMY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84978147678     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2016.57.5.1192     Document Type: Article

References (34)

1. Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn HJ, et al. The basic facts of korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database. J Breast Cancer 2014; 17: 99-106.
2. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32.
3. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92: 1143-50.
4. Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 2003; 98: 697-702.
5. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-41.
6. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391-5.
7. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
8. Ahn SG, Lee HM, Lee SA, Jeong J, Lee HD. Long-term survival analysis of korean breast cancer patients at a single center: improving outcome over time. Yonsei Med J 2014; 55: 1187-95.
9. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350-60.
10. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009; 18: 125-32.
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
12. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21: 50-7.
13. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
14. Chen X, Yu X, Chen J, Zhang Z, Tuan J, Shao Z, et al. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors. Cancer 2013; 119: 2366-74.
15. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429-34.
16. Harissis HV, Ziogas D, Baltogiannis G. Mastectomy vs breast-conserving surgery: an old dilemma comes again for early breast cancer. Ann Surg Oncol 2010; 17: 1966-7.
17. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009; 15: 4181-90.
18. Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol 2011; 18: 2858-65.
19. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-8.
20. Wang J, Xie X, Wang X, Tang J, Pan Q, Zhang Y, et al. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol 2013; 22: 247-55.
21. Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol 2013; 20: 3469-76.
22. Bhatti AB, Khan AI, Siddiqui N, Muzaffar N, Syed AA, Shah MA, et al. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy. Asian Pac J Cancer Prev 2014; 15: 2577-81.
23. Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg 2014; 149: 252-8.
24. Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 29: 2852-8.
25. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-7.
26. Cho JH, Park JM, Park HS, Park S, Kim SI, Park BW. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. J Surg Oncol 2013; 108: 531-6.
27. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006; 56: 37-47.
28. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012; 23 Suppl 6: vi7-12.
29. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-8.
30. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010; 17: 173-6.
31. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011; 29: 3885-91.
32. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 2014; 25: 1004-11.
33. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
34. Moran MS. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making? Am Soc Clin Oncol Educ Book 2014: e32-6.